Health
Johnson & Johnson’s (JNJ) COVID-19 vaccine would have an edge over others without this glitch – AlphaStreet
Johnson & Johnson (NYSE: JNJ) saw its shares climb 2% on Thursday after the company reported positive results from the early-stage trials of its COVID-19 vaccine a day ago. The stock has gained 9% in the past three months and over 8% in the past one year. The companys vaccine candidate has an advantage over its competitors in terms of dosage and storage but this is being hindered by manufacturing issues.
Trial results
On Wednesday, the results from J&Js interim Phase 1/2a trial were published in…
-
Business23 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News22 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General17 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News19 hours agoTips to improve engagement – Proctor